Retatrutide vs Survodutide
Extensively Studied vs Extensively Studied
monitor Mechanism-based · 55% Both Retatrutide and Survodutide affect insulin sensitivity or blood glucose. Monitor fasting glucose and HbA1c. Consider adding an insulin sensitizer (metformin/berberine).
Molecular Data
Retatrutide Survodutide
Weight 4,731.33 Da ~4,500 Da
Half-life ~6 days Approximately 6 days (109-115 hours)
Chain 39 amino acids 29 amino acids
Type Triple GLP-1/GIP/glucagon agonist Peptide with fatty acid acylation
Key Benefits
Retatrutide
01 Superior weight loss (24.2% at 48 weeks)
02 Improved glycemic control (HbA1c reduction up to 2.16%)
03 Enhanced cardiovascular benefits
04 Hepatic fat reduction (up to 82%)
05 Triple mechanism addresses obesity through multiple pathways
Survodutide
01 Superior weight loss vs monotherapy (14.9% at 46 weeks)
02 Once-weekly convenient dosing
03 Proven efficacy in obesity, MASH, and Type 2 diabetes
04 62% MASH improvement in clinical trials
Dosing Protocols
Retatrutide
0.5mg starting, titrate up to 8-12mg weekly / Once weekly (same day each week)
Starting Dose (Week 1-4) 0.5mg Once weekly
Low Maintenance (Week 4-8) 1mg Once weekly
Escalation (Week 8-12) 2mg Once weekly
Moderate (Week 12-16) 4mg Once weekly
Advanced (Week 16-20) 8mg Once weekly
Maximum Efficacy (Week 20+) 12mg Once weekly
Survodutide
0.6mg starting, titrate up to 3.6-6.0mg weekly / Once weekly (same day each week)
Obesity - Conservative Start 0.6mg titrated over 24 weeks Once weekly with 4-week intervals
Obesity - Standard Protocol 3.6-6.0mg Once weekly
MASH Treatment 2.4-4.8mg Once weekly
Type 2 Diabetes 0.3-2.7mg Once weekly
Side Effects
Retatrutide
Gastrointestinal effects (nausea, vomiting, diarrhea)—typically mild to moderate
Heart rate increases—common especially in first 24 weeks
Appetite suppression
Mild dehydration
Survodutide
Nausea (40-66%)
Diarrhea (25-49%)
Vomiting (15-41%)
Slight heart rate increase (mean 2-5 bpm)
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome
Severe renal impairment
Not recommended in pregnancy or breastfeeding
Use contraception during treatment
Research Evidence
Retatrutide Survodutide
Status Extensively Studied Extensively Studied
References 6 studies 3 studies
Latest 2025-10 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.